Nantomics, LLC

Nant Holdingsip, LLC

Five3 Genomics, LLC

Nanthealth, Inc.

University of California

Nantbio, Inc.

Nantcell, Inc.

Other

Stephen Charles Benz

Patrick Soon-Shiong

Charles Joseph Vaske

John Zachary Sanborn

Shahrooz Rabizadeh

Kayvan R Niazi

Andrew Nguyen

Christopher W Szeto

Joshua M Stuart

David H Haussler

Rahul Chaturvedi

Nicholas James Witchey

Mustafa Jaber

Oleksandr V Buzko

Liudmila A Beziaeva

Paul Weingarten

Nicole Hensley

Bing Song

Kamil A Wnuk

Heather McFarlane

Hermes J Garban

Connie Tsai

Chad Garner

Kevin B Givechian

Hans G Klingemann

Chunlin Tao

Laurent H Boissel

Barry J Simon

Jay Nelson

David Haussier

Jay Gardner Nelson

Andrew J Sedgewick

Mark Johnson

Rahul Parulkar

Kayvan Niazi

An immune gene expression signature is associated with favorable clinical features in Treg-enriched tumor samples and can be used to predict immunogenicity of a tumor, overall survival, and/or chemosensitivity.

Method of characterizing a tumor based on an immune gene expression signature in regulatory T cell (Treg)-enriched tumor samples

Certain universal neoepitopes and cancer specific neoepitopes and methods therefor are presented that may be used in immunotherapy and cancer diagnosis. Preferred therapeutic and diagnostic compositions include antibodies or fragments thereof that bind to neoepitopes on cancer cells.

AGGF1 immunogenic compositions

Healthcare object (HCO) discriminator systems and methods are presented. Systems can obtain a digital representation of a scene via a sensor interface. An HCO discriminator platform analyzes the digital representation to discriminate objects within the scene as being associated with a type of HCO or as being unrelated to a type of HCO. Once the HCO recognition platform determines that a type of HCO is relevant, it instantiates an actual HCO. The HCO can be routed to one or more destinations based on routing rules generated from a template or based on the manner in which the objects in the scene were discriminated.

Healthcare object recognition, systems and methods

Contemplated systems and methods employ chimeric reference sequences that include a plurality of viral genome sequences to identify/quantify integration and co-amplification events. Most typically, the viral genome sequences are organized in the chimeric reference sequences as single chromosomes and the chimeric reference sequences are in BAM format.

Systems, methods, and compositions for viral-associated tumors

A method of determining a region of interest in an image of tissue of an individual by an apparatus including processing circuitry may include executing, by the processing circuitry, instructions that cause the apparatus to partition an image of tissue of an individual into a set of areas, identify a tissue type of each area of the image, and apply a classifier to the image to determine a region of interest, the classifier being configured to determine regions of interest based on the tissue types of the set of areas of the image.

Deep learning models for region of interest determination

A method of determining a clinical value for an individual based on a tumor in an image by an apparatus including processing circuitry may include executing, by the processing circuitry, instructions that cause the apparatus to determine a lymphocyte distribution of lymphocytes in the tumor based on the image; apply a classifier to the lymphocyte distribution to classify the tumor, the classifier having been trained to classify tumors into a class selected from at least two classes respectively associated with lymphocyte distributions; and determine the clinical value for the individual based on prognoses of individuals with tumors in the class into which the classifier classified the tumor.

Deep learning models for tumor evaluation

Contemplated antiviral/cancer treatments comprise analysis of neoepitopes from viral DNA that has integrated into the host genome, and design of immunotherapeutic agents against such neoepitopes.

Viral neoepitopes and uses thereof

The invention provides a method of validating the therapeutic composition that is prepared for immunotherapy of a tumor or cancer. The method includes, triggering of an immune response to a neoepitope of a subject's tumor by: a) obtaining neoepitope sequence data from the tumor of a subject; b) obtaining immune competent cells; c) using the neoepitope sequence data to generate a neoepitope presentation system; d) triggering an immune response by contacting the immune competent cells with the neoepitope presentation system; and e) quantifying the triggering of the immune response from the contacted immune competent cells.

Method of validating the triggering of an immune response to a neoepitope of a tumor with t-cells

Various devices, systems, structures and methods are disclosed related to securely authorizing a transaction by synchronizing digital genomic data with associated synthetic genomic variants. An embodiment of the present invention utilizes digital genomic data associated with an entity, such as a person, who may utilize a genome-based security device to complete a transaction. In one embodiment, a person may use a genome-based security device to communicate with an external device over a wireless or other communication interface, synchronize digital genomic data and an associated synthetic variant received from the external device with digital genomic data and associated synthetic variant stored on the genome-based security device.

Synthetic genomic variant-based secure transaction devices, systems and methods

Deep learning models for region-of-interest determination

Growing community of inventors

Santa Cruz, CA, United States of America

Stephen Charles Benz